Shots:

• The P-III (POLARIX) study evaluates the efficacy, safety, and PK of Polivy + R-CHP vs R-CHOP in a ratio (1:1) in 879 patients with previously untreated DLBCL
• The results showed an improvement in PFS after a median follow-up of 28.2mos, 27% reduction in the risk of disease progression, relapse, or death, safety outcomes were consistent with those seen in previous trials & the safety profile was comparable for Polivy + R-CHP vs R-CHOP. The results were presented at ASH 2021 & published in the NEJM
• Polivy is used as an off-the-shelf, fixed-duration treatment option in the R/R DLBCL setting and is approved in combination with bendamustine and Rituxan in 70+ countries globally, including EU and the US

Ref: Businesswire | Image: Genentech